(Q34782021)

4 August 2017

1 reference

title

Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? (English)

1 reference

adaptive radiation therapy

4 August 2017

main subject

0 references

1 reference

Andrew Vickers

5

0 references

author name string

Brian D Lawenda

1

1 reference

4 August 2017

Kara M Kelly

2

1 reference

4 August 2017

Elena J Ladas

3

1 reference

4 August 2017

Stephen M Sagar

4

1 reference

4 August 2017

Jeffrey B Blumberg

6

1 reference

4 August 2017

language of work or name

English

0 references

publication date

27 May 2008

1 reference

Journal of the National Cancer Institute

4 August 2017

published in

1 reference

4 August 2017

volume

100

1 reference

4 August 2017

issue

11

1 reference

4 August 2017

page(s)

773-783

1 reference

Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Effect of vitamin B12, folate, and dietary supplements on breast carcinoma chemotherapy--induced mucositis and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Use of antioxidants during chemotherapy and radiotherapy should be avoided.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Vitamin E protects DNA from oxidative damage in human hepatocellular carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Cancer chemoprevention through dietary antioxidants: progress and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Vitamin C pharmacokinetics: implications for oral and intravenous use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Commentary: the pharmacological antioxidant amifostine -- implications of recent research for integrative cancer care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Antioxidants and cancer therapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

The use of antioxidant therapies during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

β-Carotene concentration in buccal mucosal cells with and without dysplastic oral leukoplakia after long-term β-carotene supplementation in male smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

Weekly cisplatin +- glutathione in relapsed ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN148

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJN148

1 reference

4 August 2017

1 reference